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ABSTRACT
Objective: To evaluate causes of hospitalization (due to complications of iron overload and
other causes) in beta-Thalassemic patients.
Methodology: This study was performed on 244 patients with major beta-Thalassemia
admitted in Taleghani hospital of Gorgan between 2000 and 2007. Causes of hospitalization
(due to complications of iron overload and other causes) were evaluated. Data were analyzed
with SPSS software.
Results: The most common causes of hospitalization due to iron overload were diabetes
mellitus (31.6%) and heart failure (16.4%). The most common clinical findings were weakness
and fatigue.
Conclusion: We perceive increased frequency of diabetes mellitus in this center compared to
other studies in Iran and abroad. Therefore glucose tolerance test and genotypic research for
IVS II nt 745 are recommended in Thalassemic patient in this area.
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INTRODUCTION
Blood transfusion therapy significantly increases
life expectancy of beta-Thalassemic patients by con-
trolling anemia and its squeals. But this treatment
leads to progressive deposition of iron in tissues,
posing significant risk of severe cardiac, endocrino-
logical, and hepatic complications, which are fatal if
not prevented.1 Today many of the complications of
Thalassemia seen in developed countries are the
result of iron overload. fibrosis and cirrhosis in the
liver, diabetes mellitus in the beta cells of the pan-
creas, growth retardation and hypogonadotropic hy-
pogonadism in the pituitary, testis, and ovaries, hy-
pocalcaemia and osteoporosis in the parathyroid, and
arrhythmias, myocarditis, and intractable cardiac
failure in the heart.2 Thus, iron overload, whether
through increased iron absorption caused by eryth-
ropoietic activity or as a result of blood transfusion,
constitutes the most important complications and
major focus of clinical management in
beta-Thalassemia.
Most of the pathologic processes develop slowly
and usually are not apparent until the 2nd decade of
life. In untransfused patients, these abnormalities de-
velop more slowly. Diabetes mellitus is a frequent
and often under recognized complication of Thalas-
semia, which is due both to pancreatic
hypoproduction and (at least in some cases) to
insulin resistance.3
Considering that Gorgan is a city located beside
Caspian sea and is assumed as one of the prevalent
areas of beta Thalassemia, statistical rendering of iron
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overload is important information for developing
facilities for patients.
METHODOLOGY
The target population of this study was patients
with beta-Thalassemia major admitted to Taleghani
hospital of Gorgan (a city located in the north of Iran)
between 21 March 2000 and 20 March 2007.
Causes of hospitalization due to complications of
iron overload (diabetes mellitus, cardiac disease and
hypocalcaemia) and other causes such as respiratory
tract infection, gastrointestinal infection, arthritis,
cellulites and reaction to transfusion, age and sex
were evaluated. Data were analyzed with SPSS soft-
ware (v: 13.0) and compared with other reports ob-
tained from developing and developed countries.
RESULTS
Of our 244 cases, 126 cases (51.6%) were female
and 118 cases (48.4%) were male. The range of pa-
tients, age was between 2.5 months and 25 years.
Diabetes mellitus was found in 31.6% of patients (77
cases); arrhythmia and heart failure were found in
16.4% of patients (40 cases) and hypocalcaemia was
found in 11.9% of patients (29 cases) (Figure-1). None
of patients were less than 5 years old had diabetes
mellitus and hypocalcaemia and none of patients
were less than 2 years old had cardiac disease
(Table-I). The youngest patient (2.5 months old) had
pneumonia and the oldest patient (25 years old) had
diabetes mellitus. Frequency of other causes of
hospitalization is shown in Figure-2 and Table-II.
DISCUSSION
The Thalassemias are common monogenic disor-
ders of hemoglobin synthesis. Beta-Thalassemias are
the most important among the Thalassemia syn-
dromes and have become a world wide clinical prob-
lem due to an increasing immigrant population.
Blood transfusion and increased gastrointestinal iron
absorption result in iron overload and tissue
damage.4
Patients with Thalassemia major have traditionally
succumbed to the cardiac complications of iron over-
load. Recurrent pericarditis distinguished by char-
acteristic pain, fever, and a friction rub may be ini-
tial manifestation of myocardial iron deposition and
occasionally requires pericardectomy to relieve con-
striction, ventricular tachycardia and fibrillation or
sever refractory congestive heart failure.3
Cardiac complication is one of the major causes of
death in patients with Thalassemia major. Heart rate
Fig-1: Frequency of hospitalization of beta-Thalassemia
with causes of iron overload.
Fig-2: Frequency of hospitalization of beta-Thalassemia
without causes of iron overload.
Table-I: Frequency of hospitalization of beta-Thalassemia
with causes of iron overload in age groups.
                  Age (year)
    Causes < 2 2-5 5-15 >15
of  hospitalization
Diabetes mellitus 0 0 33.8 66.2
Heart disease 0 2.5 47.5 50
Hypocalcemia 0 0 62.1 37.9
Table-II: Frequency of hospitalization of
beta-Thalassemia without causes of iron
overload in age groups.
                 Age (year)
Causes < 2 2-5 5-15 >15
of  hospitalization
Respiratory 23.1 0 43.6 33.3
  tract infection
GI tract infection 9.1 18.2 57.6 15.1
Arthritis and 0 0 29.4 70.6
  Cellulitis
Reaction to 0 0 71.4 28.6
  transfusion
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variability is a noninvasive index of neuronal modu-
lation of heart rate.5 Heart disease represents the main
determinant of survival in beta-Thalassemia.6
Aessopas assessed clinically and
echocardiographically 202 Thalassemia major pa-
tients aged 27.3±6.3 years and 75 age and sex-
matched healthy controls. Overt cardiac disease was
encountered in 14 patients (6.9%).7 There were 211
patients included in study of “Durong” in Thailand.
Their ages ranged from 2.6 to 18.2 years. Cardiac in-
volvement was found in 26 patients (12.3%).8 In our
study cardiac involvement was found in 40 patients
(16.4%). That is higher than world wide range. Al-
though results of our study are similar to Hong Kong
study.9
Cunningham performed a cross-sectional study in
cancer institute and Harvard medical school on 342
patients in the registry of the National Institutes of
Health-Sponsored Thalassemia clinical research net-
work. None of patients were 15 years old or younger
and 5% of patients aged 16-24 years had heart
disease requiring medication.10
In our study none of the patients were 2 years old
or younger, 6.2% of patients aged 2-5 years, 16.5% of
patients aged 5-15 years and 22.2% of patients aged
higher than 15 years had disease requiring medica-
tion. These finding may be results of poor disease
control and management in early life in our center.
Endocrine disorders commonly associated with
Thalassemia in the United States today are gener-
ally thought to be secondary to the effects of chronic
iron loading.3 Fasting blood glucose levels are sig-
nificantly elevated even in patients aged 5-10 years
whose iron burden is 5 to 209. When glucose toler-
ance tests are performed as many as 50% of Thalas-
semic patients have chemical diabetes defined by
glucose tolerance.3
Galati prospectively evaluated glucose tolerance
in 84 patients over one year. 7.9% of patients had
diabetes or impaired glucose tolerance.11 In Hong
Kong 232 patients were studied at a median age of
15.5 years (range 1.4-30.3 years). Cardiomyopathy
and diabetes mellitus occurred in 15.1% and
8.6% of patients with Thalassemia major
respectively.9
In Egyptian beta-Thalassemic patients the preva-
lence of diabetes was 10.4% (5 of 48).12 To identify
prevalence of endocrine dysfunction in Iranian with
beta-Thalassemia, Karami assessed pancreatic func-
tion in 150 beta-Thalassemia patients aged 10-22
years at the pediatrics unit, Shiraz University of
Medical Sciences. Type 1 diabetes mellitus was found
in 7.3% with age 13.9±2.8 years.13
In our study diabetes mellitus was found in 31.6%
of patients (77 cases); therefore, we perceive an in-
creased frequency of diabetes mellitus in our center
compared to other studies in Iran and abroad. The
high frequency of diabetes mellitus in our study may
be a result of poor disease control and management.
On the other hand, glucose intolerance generally cor-
relates with genetic predisposition and an associa-
tion between diabetes and genotyping IVS II nt 745
has found. Therefore test of blood glucose and
glucose tolerance every 6 months and genotypical
research for IVS II nt 745 are recommended in
Thalassemia patients in our center to detect early
occurrence of diabetes.
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